Resources and other considerations Acceptability and feasibility Remdesivir is administered as one in travenous infusion daily over 10 consecutive days, and rather than in an outpa tient setting, this is more easily operationalized in hospitalized patients with critical disease. Obstacles to access in LMICs due to c ost, feasibility and availability are of concern (30). Challenges in shared decisionmaking and in c ommunicating the harms v ersus benefits of remdesivir may also be incr eased in LMICs.